Omeros Co. (NASDAQ:OMER) Receives $23.40 Consensus Price Target from Brokerages


Share on StockTwits

Omeros Co. (NASDAQ:OMER) has been given an average rating of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $23.40.

A number of research firms have issued reports on OMER. UBS Group began coverage on shares of Omeros in a research report on Monday, February 1st. They set a “buy” rating and a $25.00 target price on the stock. HC Wainwright upped their target price on shares of Omeros from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, January 20th.

NASDAQ OMER traded down $0.56 on Thursday, hitting $18.57. 535,711 shares of the company were exchanged, compared to its average volume of 725,516. The firm has a 50 day moving average of $18.72 and a two-hundred day moving average of $16.09. The company has a market cap of $1.15 billion, a P/E ratio of -7.80 and a beta of 1.65. Omeros has a 1-year low of $9.25 and a 1-year high of $25.46.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Sunday, February 28th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.09. The company had revenue of $10.63 million for the quarter, compared to analyst estimates of $18.26 million. On average, analysts expect that Omeros will post -1.97 EPS for the current fiscal year.

In related news, CEO Gregory A. Md Demopulos sold 72,613 shares of the stock in a transaction that occurred on Thursday, April 8th. The stock was sold at an average price of $17.84, for a total transaction of $1,295,415.92. Following the completion of the sale, the chief executive officer now directly owns 2,064,393 shares of the company’s stock, valued at approximately $36,828,771.12. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Michael A. Jacobsen sold 10,000 shares of the stock in a transaction that occurred on Friday, February 19th. The stock was sold at an average price of $22.64, for a total value of $226,400.00. Following the sale, the chief accounting officer now directly owns 24,000 shares of the company’s stock, valued at $543,360. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 92,613 shares of company stock valued at $1,753,115. 11.30% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Creative Financial Designs Inc. ADV bought a new stake in Omeros during the 1st quarter worth approximately $91,000. Sonora Investment Management LLC increased its stake in Omeros by 81.7% during the 4th quarter. Sonora Investment Management LLC now owns 6,540 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 2,940 shares in the last quarter. Great West Life Assurance Co. Can increased its stake in Omeros by 192.0% during the 3rd quarter. Great West Life Assurance Co. Can now owns 8,650 shares of the biopharmaceutical company’s stock worth $252,000 after purchasing an additional 5,688 shares in the last quarter. Miramar Capital LLC bought a new position in shares of Omeros during the 4th quarter worth approximately $256,000. Finally, Hsbc Holdings PLC grew its stake in shares of Omeros by 10.4% during the 4th quarter. Hsbc Holdings PLC now owns 12,677 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 1,190 shares in the last quarter. 56.63% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: Is it Safe to Invest in Commodities?

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.